Overview
Mark Rubinshtein’s practice focuses on patent litigation and prosecution for clients in the chemical and pharmaceutical industries.
Dr. Rubinshtein earned his J.D. at University of San Diego School of Law. Prior to law school, Dr. Rubinshtein obtained a B.A. in chemistry and M.S. in chemical engineering from Columbia University and completed his Ph.D. in organic chemistry in 2011 at UC San Diego. His graduate work focused on developing targeted small molecule therapeutics for Alzheimer’s disease and on devising synthetic methods for the preparation of side-chain functionalized biodegradable and biocompatible polymers.
Dr. Rubinshtein joined the firm in 2016.
Education
- University of San Diego School of Law (USD) (J.D., 2016), magna cum laude, Order of the Coif
- University of California - San Diego (Ph.D. Organic Chemistry, 2011), Thesis Ttitle: Synthesis and applications of side chain-functionalized polylactic acid-based polymers and studies toward a chemical method to degrade Alzheimer's disease-related beta-amyloid peptides.
- Columbia University (M.S. Chemical Engineering, 2003)
- Columbia University (B.A. Chemistry, 2001), magna cum laude, departmental honors in chemistry
Affiliations
San Diego Intellectual Property Law Association
News & Insights
Articles
Contributor, Knobbe Martens Litigation Blog
Contributor, Knobbe Martens PTAB Blog
Author, Knobbe Medical Blog
- Delaware Court Denies Preliminary Injunction Seeking to Block Liquidia’s YUTREPIA Launch
- First At-Home Artificial Insemination Kit Receives FDA Clearance
- FDA Approves Neuralink to Begin Human Trials of Brain Implants
- BioNTech to Ship Modular mRNA Vaccine Factory to Rwanda
- U.S. FDA Approves Monkeypox Treatment Formulation
- Two Drugs Recalled Due to Manufacturing Issues
- FDA Approves First Generic Epinephrine Autoinjectors
- Cyberdyne Bringing HAL Cyborg Exoskeleton to US Market
- Da Volterra Develops Device to Combat Antibiotic Resistance
- FDA Approves Prickless Glucose Monitoring System
Latest Updates and News
Delaware Court Denies Preliminary Injunction Seeking to Block Liquidia’s YUTREPIA Launch
The United States District Court for the District of Delaware recently denied United Therapeutics Corporation‘s motion for a preliminary injunction. The motion sought to prevent Liquidia Technologies, Inc. from launching its YUTREPIA, which is used to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). YUTREPIA is an inhaled dry power formulation of treprostinil delivered through a palm-sized inhalation device.
First At-Home Artificial Insemination Kit Receives FDA Clearance
Mosie Baby, a Texas-based fertility care company, has received clearance from the U.S. Food and Drug Administration for its over-the-counter intravaginal insemination kit. The kit was developed for those who are unable to conceive with intercourse or for whom intercourse is not an option. It is estimated that one in six people globally is affected by infertility. The kit comes with two syringes and two collection cups for semen collection. The syringe includes a barrel-free tip and slit opening for semen transfer. The kit can be used with either fresh or cryogenically frozen semen and the instructions for use indicate it can be used during the ovulatory phase of the menstrual cycle.
FDA Approves Neuralink to Begin Human Trials of Brain Implants
Neuralink, the biotechnology company founded by Elon Musk, has received approval from the U.S. Food and Drug Administration (FDA) to commence human trials of its implantable brain-computer interface device. Recruitment for the clinical trial has not yet started.
BioNTech to Ship Modular mRNA Vaccine Factory to Rwanda
Biopharmaceutical New Technologies (BioNTech), the global immunotherapy company based in Mainz, Germany, is scheduled to ship its BioNTainer modular mRNA vaccine factory to Rwanda. According to BioNTech’s press release, the modular factory consists of six ISO-sized shipping containers that will arrive in Rwanda sometime in early 2023. Reports indicate that the modular units were manufactured in Germany and will be filled and finished by local partners in Ghana and South Africa.
U.S. FDA Approves Monkeypox Treatment Formulation
SIGA Technologies Inc., a New York-based pharmaceutical company, has received approval from the U.S. Food and Drug Administration (FDA) for an intravenous formulation of TPOXX (tecovirimat) for the treatment of smallpox. The U.S., Canada, and Europe have approved an oral formulation for treating smallpox, and Europe has also approved it for treating monkeypox and cowpox. The newly approved intravenous formulation provides an option for patients who are unable to swallow.
Two Drugs Recalled Due to Manufacturing Issues
(December 13, 2021) Two pharmaceutical companies have issued recalls in December due to manufacturing issues that may impact the safety and quality of their drug products.